Global biotechnology company Xtant Medical Holdings received approval from the New York Stock Exchange for its plan to regain compliance with the continued listing standards regarding stockholders' equity.
Four things to know:
1. Xtant's plan was submitted on May 3 and has been granted a plan period through October 4, 2020. The company did not outline its plan for compliance in its press release.
2. The firm's common stock will still be listed on the NYSE through Oct. 4, 2020. Throughout that time, Xtant is subject to review to ensure the company is making progress.
3. Xtant's shares of common stock could be delisted from the NYSE American if the company doesn't make progress according to its plan.
4. Xtant focuses on surgical solutions for the treatment of spinal disorders.